Project Details
| Short title | A Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma |
|---|---|
| Status | Finished |
| Effective start/end date | 31/01/11 → 31/03/21 |
Funding
- Uhb Nhs Trust